References
- Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, . Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27:3584–90.
- Bex A, Van der Veldt AA, Blank C, Van den Eertwegh AJ, Boven E, Horenblas S, . Neoadjuvant sunitinib for surgically complex advanced renal cell cancer of doubtful resectability: Initial experience with downsizing to reconsider cytoreductive surgery. World J Urol 2009;27:533–9.
- Jonasch E, Wood CG, Matin SF, Tu SM, Pagliaro LC, Corn PG, . Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27:4076–81.
- Van der Veldt AA, Meijerink MR, Van den Eertwegh AJ, Bex A, De Gast G, Haanen JB, . Sunitinib for treatment of advanced renal cell cancer: Primary tumor response. Clin Cancer Res 2008;14:2431–6.
- Amin C, Wallen E, Pruthi RS, Calvo BF, Godley PA, Rathmell WK. Preoperative tyrosine kinase inhibition as an adjunct to debulking nephrectomy. Urology 2008;72:864–8.
- Di SF, Sciarra A, Parente U, Andrea A, Von Heland M, Panebianco V, . Neoadjuvant therapy with sorafenib in advanced renal cell carcinoma with vena cava extension submitted to radical nephrectomy. Urol Int 2008;80:451–3.
- Harshman LC, Srinivas S, Kamaya A, Chung BI. Laparoscopic radical nephrectomy after shrinkage of a caval tumor thrombus with sunitinib. Nat Rev Urol 2009;6:338–43.
- Karakiewicz PI, Suardi N, Jeldres C, Audet P, Ghosn P, Patard JJ, . Neoadjuvant sutent induction therapy may effectively down-stage renal cell carcinoma atrial thrombi. Eur Urol 2008;53:845–8.
- Patard JJ, Thuret R, Raffi A, Laguerre B, Bensalah K, Culine S. Treatment with sunitinib enabled complete resection of massive lymphadenopathy not previously amenable to excision in a patient with renal cell carcinoma. Eur Urol 2009;55:237–9.
- Robert G, Gabbay G, Bram R, Wallerand H, Deminiere C, Cornelis F, . Case study of the month. Complete histo-logic remission after sunitinib neoadjuvant therapy in T3b renal cell carcinoma. Eur Urol 2009;55:1477–80.
- Shuch B, Riggs SB, LaRochelle JC, Kabbinavar FF, Avakian R, Pantuck AJ, . Neoadjuvant targeted therapy and advanced kidney cancer: Observations and implications for a new treatment paradigm. BJU Int 2008;102:692–6.
- Zangari M, Fink LM, Elice F, Zhan F, Adcock DM, Tricot GJ. Thrombotic events in cancer patients receiving antiangiogenesis agents. J Clin Oncol 2009;27:4865–73.
- Bex A, Kerst M, Mallo H, Meinhardt W, Horenblas S, De Gast GC. Interferon alpha 2b as medical selection for nephrectomy in patients with synchronous metastatic renal cell carcinoma: A consecutive study. Eur Urol 2006;49:76–81.
- Thomas AA, Rini BI, Lane BR, Garcia J, Dreicer R, Klein EA, . Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma. J Urol 2009;181:518–23.
- Margulis V, Wood CG. Cytoreductive nephrectomy in the era of targeted molecular agents: Is it time to consider presurgical systemic therapy? Eur Urol 2008;54:489–92.
- Johannsen M, Florcken A, Bex A, Roigas J, Cosentino M, Ficarra V, . Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis. Eur Urol 2009;55:1430–8.